J Korean Med Sci.
2009 Jan;24(Suppl 1):S189-S194. 10.3346/jkms.2009.24.S1.S189.
The Breakdown of Preformed Peritoneal Advanced Glycation End Products by Intraperitoneal Alagebrium
- Affiliations
-
- 1Department of Internal Medicine, Dongguk University Medical Center, Gyeongju, Korea. jhlee@dongguk.ac.kr
- 2Department of Pathology, Dongguk University Medical Center, Gyeongju, Korea.
- 3Dr. Tak's Renal Clinic, Pohang, Korea.
- KMID: 1778161
- DOI: http://doi.org/10.3346/jkms.2009.24.S1.S189
Abstract
- It has been demonstrated that inhibitors of advanced glycation end products (AGE), such as aminoguanidine, can suppress peritoneal AGE in rats on peritoneal dialysis (PD). However, it is unknown whether late administration of a putative crosslink breaker, alagebrium, could reverse peritoneal AGE. We therefore compared alagebrium with aminoguanidine in their ability to reverse peritoneal AGE in rats on PD. Male Sprague-Dawley rats were randomly divided into 3 groups: group I dialyzed with 4.25% glucose solution for all exchanges; group II dialyzed with 4.25% glucose solution containing aminoguanidine, and group III dialyzed with 4.25% glucose solution containing alagebrium for last 8 weeks of 12-week dialysis period. Dialysis exchanges were performed 2 times a day for 12 weeks. Immunohistochemistry was performed using a monoclonal anti-AGE antibody. One-hour PET was performed for comparison of transport characteristics. The immunolabelling of AGE in peritoneal membrane was markedly decreased in the alagebrium group. Consistent with this, the alagebrium group exhibited significantly higher D/Do glucose and lower D/P urea, suggesting low peritoneal membrane transport. But there were no significant differences between the control and the aminoguanidine group. These results suggest that the alagebrium may be the optimal therapeutic approach, compared with treatment with inhibitors of AGE formation, in rats on PD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Role of Advanced Glycation End Products in Diabetic Vascular Complications
- Understanding and therapeutic approaches to advanced glycation end-products in chronic diseases and neurodegenerative diseases
- Alagebrium Chloride, a Novel Advanced Glycation End-Product Cross Linkage Breaker, Inhibits Neointimal Proliferation in a Diabetic Rat Carotid Balloon Injury Model
- Letter: The Association between Serum Endogenous Secretory Receptor for Advanced Glycation End Products and Vertebral Fractures in Type 2 Diabetes (Endocrinol Metab 2012;27:289-94, Cheol Ho Lee et al.)
- Inhibition of advanced glycation end product formation by burdock root extract
